This image provided by Novartis shows Rydapt. The Food and Drug Administration on Friday approved Rydapt for treating adults newly diagnosed with acute myeloid leukemia who have a genetic mutation called FLT3. Patients would take it along with chemotherapy.The drug, known chemically as midostaurin, is the first new medicine for acute myeloid leukemia in 25 years, according to the company. (Novartis via AP)
Featured Photo Galleries
Trump Transition: Here are the people Trump has picked for key positions so far
President-elect Donald Trump has announced a flurry of picks for his incoming administration. Get full coverage of the Trump transition from The Washingon Times.
Trump dances onstage, takes post-election nation by storm
President-elect Trump dances onstage
